Iatrogenic Cushing Syndrome. Author: Ha Cam Thuy Nguyen, MD; Chief Editor: Romesh Khardori, MD, PhD, FACP more... Background. Cushing syndrome, first described by Harvey in 1912, refers to signs and symptoms caused by excess free plasma glucocorticoids. Excess glucocorticoids can be from increased endogenous production or prolonged exposure to exogenous use of glucocorticoid products.
As is apparent from the above discussion, a drug target is a key molecule involved in a particular metabolic or signal transduction pathway that is specific to a disease condition or a specific disease. However, the term âdrug targetâ itself has several limitations and is debated within the pharmaceutical industry.n this respect, several points should be kept in mind. First, a drug target is a relative concept. For starters, a drug target is, just like other biomolecules, also a biomolecule involved in a transduction pathway. The difference between the two is only in their location and role in the transduction pathway.
Targeted therapy aims to disrupt specific steps or processes that are somewhat unique to the growth of cancer cells. Testing the cancer cells biopsied from patients prior to initiating drug therapy to determine the cancer's likely response to certain cancer drugs is a key emerging area of testing.heir goal has been to create drugs that disrupt a specific step in cancer growth, while doing minimal damage to normal cells. These are called targeted drugs or targeted therapy. What researchers have noted is that specific types of cancer are frequently associated with specific genetic mutations.